Ever Supreme Bio Technology Co., Ltd (TPEX:6712)
134.00
+2.50 (1.90%)
May 29, 2026, 1:30 PM CST
TPEX:6712 Revenue
Ever Supreme Bio Technology had revenue of 190.49M TWD in the quarter ending March 31, 2026, with 7.06% growth. This brings the company's revenue in the last twelve months to 1.03B, up 8.61% year-over-year. In the year 2025, Ever Supreme Bio Technology had annual revenue of 1.02B with 8.96% growth.
Revenue (ttm)
1.03B
Revenue Growth
+8.61%
P/S Ratio
11.97
Revenue / Employee
n/a
Employees
n/a
Market Cap
12.32B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.02B | 83.69M | 8.96% |
| Dec 31, 2024 | 933.81M | 175.42M | 23.13% |
| Dec 31, 2023 | 758.39M | 130.88M | 20.86% |
| Dec 31, 2022 | 627.51M | 188.67M | 42.99% |
| Dec 31, 2021 | 438.84M | 368.24M | 521.61% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| EirGenix | 1.13B |
| PharmaEngine | 963.83M |
| Medigen Vaccine Biologics | 603.68M |
| TaiMed Biologics | 601.19M |
| Tanvex BioPharma | 483.94M |
| Polaris Group | 69.27M |
| Gongwin Biopharm Holdings | 38.28M |
| AP Biosciences | 32.25M |